Renal Unit, St Helier Hospital, Epsom and St Helier University Hospitals National Health Service Trust, Epsom, United Kingdom.
Institute of Infection and Immunity, St George's University of London, London, United Kingdom.
Kidney360. 2020 Sep 10;1(11):1226-1243. doi: 10.34067/KID.0004502020. eCollection 2020 Nov 25.
Patients on dialysis with frequent comorbidities, advanced age, and frailty, who visit treatment facilities frequently, are perhaps more prone to SARS-CoV-2 infection and related death-the risk factors and dynamics of which are unknown. The aim of this study was to investigate the hospital outcomes in patients on dialysis infected with SARS-CoV-2.
Data on 224 patients on hemodialysis between February 29, 2020 and May 15, 2020 with confirmed SARS-CoV-2 were analyzed for outcomes and potential risk factors for death, using a competing risk-regression model assessed by subdistribution hazards ratio (SHR).
Crude data analyses suggest an overall case-fatality ratio of 23% (95% CI, 17% to 28%) overall, but that varies across age groups from 11% (95% CI, 0.9% to 9.2%) in patients ≤50 years old and 32% (95% CI, 17% to 48%) in patients >80 years; with 60% of deaths occurring in the first 15 days and 80% within 21 days, indicating a rapid deterioration toward death after admission. Almost 90% of surviving patients were discharged within 28 days. Death was more likely than hospital discharge in patients who were more frail (WHO performance status, 3-4; SHR, 2.16 [95% CI, 1.25 to 3.74]; =0.006), had ischemic heart disease (SHR, 2.28 [95% CI, 1.32 to 3.94]; =0.003), cerebrovascular disease (SHR, 2.11 [95% CI, 1.20 to 3.72]; =0.01), smoking history (SHR, 2.69 [95% CI, 1.33 to 5.45]; =0.006), patients who were hospitalized (SHR, 10.26 [95% CI, 3.10 to 33.94]; <0.001), and patients with high CRP (SHR, 1.35 [95% CI, 1.10 to 1.67]) and a high neutrophil:lymphocyte ratio (SHR, 1.03 [95% CI, 1.01 to 1.04], <0.001). Our data did not support differences in the risk of death associated with sex, ethnicity, dialysis vintage, or other comorbidities. However, comparison with the entire dialysis population attending these hospitals, in which 13% were affected, revealed that patients who were non-White (62% versus 52% in all patients, =0.001) and those with diabetes (54% versus 22%, <0.001) were disproportionately affected.
This report discusses the outcomes of a large cohort of patients on dialysis. We found SARS-CoV-2 infection affected more patients with diabetes and those who were non-White, with a high case-fatality ratio, which increased significantly with age, frailty, smoking, increasing CRP, and neutrophil:lymphocyte ratio at presentation.
经常患有多种合并症、年龄较大且身体虚弱、频繁前往治疗机构的透析患者,或许更容易感染 SARS-CoV-2 并因此死亡,但其风险因素和动态变化尚不清楚。本研究旨在探讨感染 SARS-CoV-2 的透析患者的住院结局。
分析了 2020 年 2 月 29 日至 2020 年 5 月 15 日期间 224 例确诊为 SARS-CoV-2 的血液透析患者的数据,使用亚分布风险比(SHR)评估的竞争风险回归模型分析死亡的潜在危险因素和结局。
粗数据分析提示总病死率为 23%(95%CI,17%至 28%),但在不同年龄组中存在差异,50 岁及以下患者的病死率为 11%(95%CI,0.9%至 9.2%),80 岁及以上患者的病死率为 32%(95%CI,17%至 48%);60%的死亡发生在入院后的前 15 天,80%发生在 21 天内,表明入院后患者的病情迅速恶化导致死亡。在 28 天内,几乎 90%的存活患者出院。与那些病情较轻(世界卫生组织体力状态,3-4 分;SHR,2.16[95%CI,1.25 至 3.74];=0.006)、患有缺血性心脏病(SHR,2.28[95%CI,1.32 至 3.94];=0.003)、脑血管疾病(SHR,2.11[95%CI,1.20 至 3.72];=0.01)、有吸烟史(SHR,2.69[95%CI,1.33 至 5.45];=0.006)、住院患者(SHR,10.26[95%CI,3.10 至 33.94];<0.001)和 C 反应蛋白(SHR,1.35[95%CI,1.10 至 1.67])和中性粒细胞与淋巴细胞比值(SHR,1.03[95%CI,1.01 至 1.04])较高的患者相比,出院的可能性更大。我们的数据不支持与死亡风险相关的性别、种族、透析史或其他合并症的差异。然而,与在这些医院接受治疗的所有透析患者(13%)相比,我们发现非白人(62%比所有患者中的 52%,=0.001)和患有糖尿病(54%比 22%,<0.001)的患者受影响的比例不成比例。
本报告讨论了一项大型透析患者队列的结局。我们发现 SARS-CoV-2 感染影响了更多患有糖尿病和非白人的患者,病死率较高,且随着年龄、虚弱程度、吸烟、C 反应蛋白和中性粒细胞与淋巴细胞比值的增加,病死率显著增加。